Method of Immunization Against the 4 Serotypes of Dengue Fever

Abstract

The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and (b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever, in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).

1 - 7 . (canceled) 
     
     
         8 . An immunization kit against dengue fever virus comprising container (a) a first container containing a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, (b) a second container containing a tetravalent vaccine comprising vaccinal viruses for the 4 serotypes of dengue fever. 
     
     
         9 . The immunization kit as claimed in  claim 8 , comprising at least:
 (a) a first container containing a monovalent vaccine comprising a VDV1 or VDV2 vaccinal virus,   (b) a second container containing a tetravalent vaccine comprising Chimerivax™ DEN-1,2,3 and 4.   
     
     
         10 . The immunization kit as claimed in  claim 9 , wherein the monovalent vaccine comprises 10 4  DICC 50  of VDV1 or VDV2 and the tetravalent vaccine comprises about 10 5  DICC 50  of Chimerivax™ DEN-1,2,3 and about 10 3  DICC 50  of Chimerivax™ DEN-4. 
     
     
         11 . An immunization kit against dengue fever virus comprising container (a) a first container containing a monovalent vaccine comprising a VDV1 or VDV2 vaccinal virus, (b) a second container containing a tetravalent vaccine comprising vaccinal viruses for the 4 serotypes of dengue fever. 
     
     
         12 . The immunization kit as claimed in  claim 11 , comprising at least:
 (a) a first container containing a monovalent vaccine comprising a VDV1 or VDV2 vaccinal virus,   (b) a second container containing a tetravalent vaccine comprising Chimerivax™ DEN-1,2,3 and 4.   
     
     
         13 . The immunization kit as claimed in  claim 12 , wherein the monovalent vaccine comprises 10 4  DICC 50  of VDV1 or VDV2 and the tetravalent vaccine comprises about 10 5  DICC 50  of Chimerivax™ DEN-1,2,3 and about 10 3  DICC 50  of Chimerivax™ DEN-4.